Methods: Retrospective review of patients seen between July 2018 and July 2019 at Purley Memorial Hospital, covering a large urban borough. Patients included in the study had prevalent moderate and severe VFFs (defined by Ghent criteria).

Results: 84 patients were included, of which there were 71 females and 13 males. Median age was 76 (IQR 67 – 82) and BMI was 25 (IQR 21 – 27), with 6% of patients noted to be underweight (BMI <18.5). 38% of patients had a family history of osteoporosis and 21% of patients reported a history of parental hip fracture. 21% of patients had experienced recurrent falls. Overall (56%) of patients were noted to have had 2-or-more previous fragility fractures. Of the femoral cohort, 24% had early menopause, 13% were nulliparous and 1% had late menarche. Of the modifiable risk factors, alcohol (24%), sedentary lifestyle (21%) and smoking (13%) were the most common. Thyroid disease (18%) was the most common medical condition associated, followed by coeliac/malabsorption (7%), endocanopathy (6%) and COPD (6%). Proton Pump Inhibitors (PPIs) and steroids were the most common medications associated with 16% and 14% of cases respectively. 73% of patients had good calcium intake and 62% had calcium supplements. Overall, 27 patients had 3-or-fewer risk factors, 35 patients had 4-to-6 risk factors, 19 had 7-to-9 risk factors, and 3 had greater than 10 risk factors.

Conclusion: Our study identified several risk factors and their prevalence. The majority of patients were female, of which 24% had early menopause. Several modifiable risk factors such as low BMI, alcohol, smoking and sedentary lifestyle were commonly seen, emphasizing the need to identify these risk factors in the initial consultation. Over half of patients (56%) had had 2-or-more previous non-VFFs, suggesting the need to screen for VFFs in patients with multiple fragility fractures at baseline assessment. A number of co-existing medical conditions were also observed with thyroid disease being the most prevalent. PPIs and steroids were the most common medications associated with 16% and 14% of cases respectively. 73% of patients had good calcium intake and 62% had calcium supplements. Overall, 27 patients had 3-or-fewer risk factors, 35 patients had 4-to-6 risk factors, 19 had 7-to-9 risk factors, and 3 had greater than 10 risk factors.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2201

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2202

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2299

AB0617

BISPHOSPHONATES DANS L’OSTÉOPOROSE ET LE RISQUE D’OSTÉONÉCROSE DE LA MÂCHOIRE, ENVIRON 896 CAS

A. R. Halidou1, K. Nassar1, S. Janani1, Université Hassan II, médecine, Casablanca, Morocco

Background: Biphosphonates (BF) are used in the treatment of osteoporosis, Paget's disease of bone, hypercalcemia and in patients with cancer. When used to treat osteoporosis, the optimal duration of treatment is 3 to 5 years; however, their long-term use has been rarely associated with osteonecrosis of the jaw. Objective: To assess the risk of developing osteonecrosis of the jaw in patients followed for osteoporosis and on biphosphonates (BF).

Methods: Type of study: retrospective study conducted at the rheumatology department of the IBN ROCHD CHU in Casablanca.

Duration: from October 2013 to October 2020 (7 years).

Inclusion criteria: all patients followed for osteoporosis in the weakening osteopathy clinic. Osteoporosis was postmenopausal in 687 patients, ie 76.67% of cases, 23.30% after the menarche. Of the modifiable risk factors, alcohol (24%), sedentary lifestyle (21%) and smoking (13%) were the most common. Thyroid disease (18%) was the most common medical condition associated, followed by coeliac/malabsorption (7%), endocanopathy (6%) and COPD (6%). Proton Pump Inhibitors (PPIs) and steroids were the most common medications associated with 16% and 14% of cases respectively. 73% of patients had good calcium intake and 62% had calcium supplements. Overall, 27 patients had 3-or-fewer risk factors, 35 patients had 4-to-6 risk factors, 19 had 7-to-9 risk factors, and 3 had greater than 10 risk factors.

Results: 896 patients were treated during this period. The average age was 62.7 years (28 to 90 years), of which 85.16% were women and 14.84% were men, for a sex ratio (F/M) of 5.74. As a history, 18.75% of patients are diabetic, 26.56% followed for breast neoplasm, 14.06% of patients had received long-term corticosteroid therapy for various pathologies such as chronic inflammatory rheumatism. Osteoporosis was postmenopausal in 687 patients, ie 76.67% of cases, 23.30% after the menarche. Of the modifiable risk factors, alcohol (24%), sedentary lifestyle (21%) and smoking (13%) were the most common. Thyroid disease (18%) was the most common medical condition associated, followed by coeliac/malabsorption (7%), endocanopathy (6%) and COPD (6%). Proton Pump Inhibitors (PPIs) and steroids were the most common medications associated with 16% and 14% of cases respectively. 73% of patients had good calcium intake and 62% had calcium supplements. Overall, 27 patients had 3-or-fewer risk factors, 35 patients had 4-to-6 risk factors, 19 had 7-to-9 risk factors, and 3 had greater than 10 risk factors.

Conclusion: Our study identified several risk factors and their prevalence. The majority of patients were female, of which 24% had early menopause. Several modifiable risk factors such as low BMI, alcohol, smoking and sedentary lifestyle were commonly seen, emphasizing the need to identify these risk factors in the initial consultation. Over half of patients (56%) had had 2-or-more previous non-VFFs, suggesting the need to screen for VFFs in patients with multiple fragility fractures at baseline assessment. A number of co-existing medical conditions were also observed with thyroid disease being the most prevalent. PPIs and steroids were the most common medications associated with 16% and 14% of cases respectively. 73% of patients had good calcium intake and 62% had calcium supplements. Overall, 27 patients had 3-or-fewer risk factors, 35 patients had 4-to-6 risk factors, 19 had 7-to-9 risk factors, and 3 had greater than 10 risk factors.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2201

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2202

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2299

AB0618

GLUCOCORTICOID INDUCED OSTEOPOROSIS PREVENTION IN THE OUTPATIENT RHEUMATOLOGY CLINIC

Z. Vaghaiwalla1, G. Kaeley1. University of Florida College of Medicine-Jacksonville, Rheumatology, Jacksonville, United States of America

Background: Patients with rheumatic disease are at risk of developing glucocorticoid induced osteoporosis (GIOP) as many are prescribed systemic oral glucocorticoids as an adjunct to their maintenance therapy. Based on the 2017 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, a good practice recommendation exists that “initial clinical fracture risk assessment should be performed as soon as possible, but at least within six months of the initiation of long term glucocorticoid treatment.”1

Long-term glucocorticoids use is defined as use of at least 3 months of corticosteroid treatment at a dose of 7.5 mg prednisone daily, as well as age less than 65. Females aged 65 or older were omitted to prevent overlap of the United States Preventative Taskforce recommendation for all women ≥ 65 years to be screened for osteoporosis with DEXA scans.2 DEXA scan orders, calcium and vitamin D prescriptions, and osteoporosis medication prescriptions were abstracted. After baseline data obtained, intervention of the rheumatology fellows and faculty, and internal medicine residents in the guidelines for GIOP prevention was implemented. In addition, a smartphrase in the electronic medical record was created for provider use when treating patients on chronic corticosteroids. Subsequently, two audit cycles were completed for retrospective chart review.

Results: Upon completion of second audit cycle, there was no change in percentage of DEXA scan orders at Clinic 1, however there was a 10% overall improvement in DEXA scan orders in the Clinic 2.

In terms of Calcium and Vitamin D prescriptions, there was an overall improvement in both clinics of 19.7% and 13.3% in Clinics 1 and 2 respectively after the second audit cycle.

Additionally, there was a 3.4% increase in osteoporosis medication prescriptions overall subsequent to the second audit cycle in Clinic 1. However in Clinic 2 there was an overall decrease in osteoporosis medication prescriptions of 6.6%.

Clinic 1 Prior to Audit Audit cycle 1 Audit cycle 2

Patient percentage without DEXA scan orders 30% 33.30% 30%

Patient percentage without Vitamin D/Calcium orders 26.40% 8.30% 6.70%

Patient percentage with osteoporosis medication 23.30% 8.30% 26.70%

Clinic 2

Patient percentage without DEXA scan orders 50% 37.00% 40%

Patient percentage without Vitamin D/Calcium orders 30% 26.00% 16.70%

Patient percentage with osteoporosis medication 23.30% 11.10% 16.70%

Conclusion: Overall, the results of the intervention were strongest for improvements in Vitamin D and Calcium orders in both clinics. Improvements in DEXA scan orders and osteoporosis medications were present in Clinic 2 and not present in Clinic 1. This reveals continued efforts and education of providers needed to be made for improvement in bone health monitoring.

REFERENCES: